Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAMES QUINTEN DEL ROSSO

Allopathic & Osteopathic Physicians Dermatology MOHS-Micrographic Surgery

NPI
1083636369
CMS profile
3970
Location
LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$739,887.44

508 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
SUN PHARMACEUTICAL INDUSTRIES INC. $120,892.87 40
E.R. Squibb & Sons, L.L.C. $82,272.64 81
GENZYME CORPORATION $75,091.80 44
Regeneron Healthcare Solutions, Inc. $65,813.93 50
Dermavant Sciences, Inc. $54,859.35 46
LEO Pharma Inc. $53,930.51 33
Arcutis Biotherapeutics, Inc. $53,683.90 39
Galderma Laboratories, L.P. $41,097.84 22
Incyte Corporation $36,138.39 28
PFIZER INC. $35,221.38 22
Lilly USA, LLC $29,842.64 27
Amgen Inc. $21,914.83 25
Ortho Dermatologics, a division of Bausch Health US, LLC $17,374.86 9
Almirall LLC $15,867.47 11
UCB, Inc. $12,330.69 8
AbbVie Inc. $9,064.87 11
Verrica Pharmaceuticals Inc. $6,720.94 6
Galderma Research & Development, LLC $3,200.00 1
LEO Pharma AS $2,820.00 1
SANOFI PASTEUR INC. $1,624.00 1
Regeneron Pharmaceuticals, Inc. $116.53 2
Janssen Biotech, Inc. $8.00 1

Page 3 of 11; records 101–150 of 508 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAMES QUINTEN DEL ROSSO

NPI 1083636369 · CMS profile ID 3970

Allopathic & Osteopathic Physicians / Dermatology / MOHS-Micrographic Surgery

LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 11; records 101–150 of 508 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1083636369?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAMES QUINTEN DEL ROSSO, NPI 1083636369, CMS profile ID 3970. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 11; records 101–150 of 508 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1083636369?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JAMES QUINTEN DEL ROSSO, NPI 1083636369, CMS profile ID 3970. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 11; records 101–150 of 508 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1083636369?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JAMES QUINTEN DEL ROSSO, NPI 1083636369, CMS profile ID 3970, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 11; records 101–150 of 508 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1083636369?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

508 matching records · $739,887.44 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 508 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 508.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Dermavant Sciences, Inc. $199.2009/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991176037 CMS
Dermavant Sciences, Inc. $36.5209/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991176041 CMS
Dermavant Sciences, Inc. $21.7409/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991176045 CMS
Dermavant Sciences, Inc. $32.6109/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991176049 CMS
Dermavant Sciences, Inc. $23.8309/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991176013 CMS
Dermavant Sciences, Inc. $7,000.0009/15/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991176017 CMS
Dermavant Sciences, Inc. $7,200.0009/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991176009 CMS
Regeneron Healthcare Solutions, Inc. $1,830.0009/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999147525 CMS
Sun Pharmaceutical Industries Inc. $6,000.0009/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053864789 CMS
Sun Pharmaceutical Industries Inc. $298.9009/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053864793 CMS
Sun Pharmaceutical Industries Inc. $178.9809/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053864797 CMS
Sun Pharmaceutical Industries Inc. $672.7509/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053864801 CMS
Sun Pharmaceutical Industries Inc. $409.2609/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053864805 CMS
Sun Pharmaceutical Industries Inc. $125.0009/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053864809 CMS
LEO Pharma Inc. $349.0009/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053465313 CMS
PFIZER INC. $3,400.0009/13/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050648765 CMS
Sun Pharmaceutical Industries Inc. $6,000.0009/13/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053864769 CMS
Sun Pharmaceutical Industries Inc. $187.6709/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053864777 CMS
Sun Pharmaceutical Industries Inc. $1,770.2409/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053864781 CMS
Sun Pharmaceutical Industries Inc. $124.2209/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053864785 CMS
Regeneron Healthcare Solutions, Inc. $7,686.0009/12/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999147517 CMS
Incyte Corporation $350.0009/11/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044370225 CMS
LEO Pharma Inc. $617.2709/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053465309 CMS
Regeneron Healthcare Solutions, Inc. $47.1509/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999147509 CMS
Dermavant Sciences, Inc. $111.6609/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991176005 CMS
PFIZER INC. $2,190.0009/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050455471 CMS
PFIZER INC. $228.7909/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050418741 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $30,959.5509/01/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059924169 CMS
PFIZER INC. $222.7908/31/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049126915 CMS
E.R. Squibb & Sons, L.L.C. $2,257.0008/30/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016296623 CMS
E.R. Squibb & Sons, L.L.C. $2,604.0008/30/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016296627 CMS
E.R. Squibb & Sons, L.L.C. $7,161.0008/30/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016296631 CMS
PFIZER INC. $3,400.0008/30/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049244893 CMS
PFIZER INC. $222.7908/30/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049542945 CMS
PFIZER INC. $457.5808/29/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050458143 CMS
PFIZER INC. $410.4608/29/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050606451 CMS
PFIZER INC. $3,400.0008/28/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049260115 CMS
E.R. Squibb & Sons, L.L.C. $2.5008/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016296589 CMS
PFIZER INC. $4,400.0008/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050507633 CMS
PFIZER INC. $94.0908/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050611057 CMS
E.R. Squibb & Sons, L.L.C. $10.6208/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016296593 CMS
PFIZER INC. $65.2708/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050627445 CMS
Galderma Laboratories, L.P. $1,580.0008/22/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059691003 CMS
E.R. Squibb & Sons, L.L.C. $3,038.0008/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016296569 CMS
E.R. Squibb & Sons, L.L.C. $6,640.0008/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016296573 CMS
Galderma Laboratories, L.P. $8,100.0008/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059690999 CMS
Lilly USA, LLC $1,200.0008/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031601031 CMS
Lilly USA, LLC $3,200.0008/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031698869 CMS
Arcutis Biotherapeutics, Inc. $6,375.0008/17/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044730385 CMS
Sun Pharmaceutical Industries Inc. $2,000.0008/17/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053864765 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $392,420.91 290
PY2020 $252,052.76 151
PY2021 $281,822.93 195
PY2022 $550,255.69 390
PY2023 $739,887.44 508
PY2024 $725,560.21 564
PY2025 $670,246.51 483

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $269,623.80 53
PY2024 Recipient $104.58 1
PY2024 Principal investigator $206,570.35 118
PY2023 Principal investigator $155,960.99 42
PY2022 Principal investigator $246,463.82 46
PY2021 Recipient $5,000.00 1
PY2021 Principal investigator $235,558.16 42
PY2020 Principal investigator $373,027.22 40
PY2019 Principal investigator $293,390.83 67

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

53 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $3,918.00 12/19/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540968
Principal investigator 1 Incyte Corporation $1,075.00 12/19/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240540989
Principal investigator 1 Incyte Corporation $1,586.00 12/19/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240540992
Principal investigator 1 Incyte Corporation $1,419.00 12/19/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240540996
Principal investigator 1 Incyte Corporation $2,168.00 12/19/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240541001
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,233.20 12/18/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH LLC
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289930
Principal investigator 1 Incyte Corporation $1,890.00 12/11/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540971
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $34,988.20 12/11/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH LLC
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289566
Principal investigator 1 Incyte Corporation $889.60 12/05/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240540981
Principal investigator 1 Incyte Corporation $5,538.00 12/04/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540963
Principal investigator 1 Incyte Corporation $5,468.50 11/26/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540955
Principal investigator 1 Incyte Corporation $10,296.60 11/26/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540960
Principal investigator 1 Incyte Corporation $1,364.40 11/21/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240540976
Principal investigator 1 Incyte Corporation $2,234.00 11/14/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540948
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $41,641.60 11/03/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH LLC
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287877
Principal investigator 1 Incyte Corporation $1,890.00 10/28/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540932
Principal investigator 1 Eli Lilly and Company $10,010.00 10/23/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187886022
Principal investigator 1 Incyte Corporation $3,209.00 10/23/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540940
Principal investigator 1 Incyte Corporation $647.00 10/22/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240540974
Principal investigator 1 Incyte Corporation $1,586.00 10/22/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240540985
Principal investigator 1 Incyte Corporation $2,168.00 10/22/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240541004
Principal investigator 1 Incyte Corporation $2,168.00 10/22/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240541008
Principal investigator 1 Incyte Corporation $73.00 10/22/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240541013
Principal investigator 1 Incyte Corporation $1,890.00 10/16/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540944
Principal investigator 1 Incyte Corporation $2,028.00 10/09/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540936
Principal investigator 1 Incyte Corporation $8,102.00 09/23/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540927
Principal investigator 1 Incyte Corporation $2,636.00 09/11/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540923
Principal investigator 1 Incyte Corporation $3,209.00 09/04/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540929
Principal investigator 1 Incyte Corporation $5,325.00 08/26/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540918
Principal investigator 1 Incyte Corporation $3,303.00 08/21/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540911
Principal investigator 1 Incyte Corporation $7,117.00 08/07/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540915
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,200.00 08/01/2025 Non-covered Recipient Entity
Jdr Dermatology Research
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1235996489
Principal investigator 1 Incyte Corporation $3,071.00 07/17/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540906
Principal investigator 1 Incyte Corporation $6,074.00 07/10/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540902
Principal investigator 1 SANOFI US SERVICES INC. $7,400.00 07/02/2025 Non-covered Recipient Entity
Jdr Dermatology Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226104708
Principal investigator 1 Incyte Corporation $7,526.00 06/24/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540898
Principal investigator 1 Incyte Corporation $1,279.00 06/19/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540892
Principal investigator 1 Incyte Corporation $5,134.00 06/12/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540888
Principal investigator 1 Incyte Corporation $1,950.00 05/27/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540872
Principal investigator 1 Incyte Corporation $975.00 05/15/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540876
Principal investigator 1 Incyte Corporation $304.00 05/08/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540884
Principal investigator 1 Incyte Corporation $2,573.00 05/02/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540880
Principal investigator 1 Incyte Corporation $1,890.00 04/17/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540863
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 04/17/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH LLC
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278198
Principal investigator 1 Incyte Corporation $3,996.00 04/10/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540868
Principal investigator 1 Incyte Corporation $4,983.00 04/03/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540858
Principal investigator 1 Eli Lilly and Company $1,084.80 03/25/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187883002
Principal investigator 1 Incyte Corporation $14,662.50 03/20/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540846
Principal investigator 1 Incyte Corporation $159.00 03/01/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540851
Principal investigator 1 Incyte Corporation $58.00 03/01/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240540854
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $12,459.00 02/12/2025 Non-covered Recipient Entity
Jdr Dermatology Research
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1235996487
Principal investigator 1 Incyte Corporation $1,494.90 01/17/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240541022
Principal investigator 1 Incyte Corporation $4,279.50 01/03/2025 Non-covered Recipient Entity
JDR DERMATOLOGY RESEARCH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240541017